Cell-to-cell variability in PI3K protein level regulates PI3K-AKT pathway activity in cell populations

Current Biology

Volumn 21, Issue 3, 2011, Pages 173-183

  Yuan, Tina L ^a,b,c   Wulf, Gerburg ^a,b   Burga, Laura ^a,b   Cantley, Lewis C ^a,b  

^a HARVARD MEDICAL SCHOOL   (United States)

^b BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EPIDERMAL GROWTH FACTOR; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHATIDYLINOSITOL 4,5 BISPHOSPHATE 3 KINASE; PROTEIN KINASE B;

ARTICLE; CELL COMMUNICATION; CELL LINE; FLOW CYTOMETRY; GENETICS; HUMAN; METABOLISM; PHOSPHORYLATION; PHYSIOLOGY; SIGNAL TRANSDUCTION;

CELL COMMUNICATION; CELL LINE; CLASS IA PHOSPHATIDYLINOSITOL 3-KINASE; EPIDERMAL GROWTH FACTOR; FLOW CYTOMETRY; HUMANS; PHOSPHATIDYLINOSITOL 3-KINASES; PHOSPHORYLATION; PROTO-ONCOGENE PROTEINS C-AKT; SIGNAL TRANSDUCTION;

MAMMALIA;

EID: 79651474934     PISSN: 09609822     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cub.2010.12.047     Document Type: Article

References (39)

1. N.Q. Balaban, J. Merrin, R. Chait, L. Kowalik, and S. Leibler Bacterial persistence as a phenotypic switch Science 305 2004 1622 1625 (Pubitemid 39296357)
2. M. Acar, J.T. Mettetal, and A. van Oudenaarden Stochastic switching as a survival strategy in fluctuating environments Nat. Genet. 40 2008 471 475 (Pubitemid 351450880)
3. A. Raj, and A. van Oudenaarden Nature, nurture, or chance: Stochastic gene expression and its consequences Cell 135 2008 216 226
4. A.A. Cohen, N. Geva-Zatorsky, E. Eden, M. Frenkel-Morgenstern, I. Issaeva, A. Sigal, R. Milo, C. Cohen-Saidon, Y. Liron, and Z. Kam Dynamic proteomics of individual cancer cells in response to a drug Science 322 2008 1511 1516
5. S.L. Spencer, S. Gaudet, J.G. Albeck, J.M. Burke, and P.K. Sorger Non-genetic origins of cell-to-cell variability in TRAIL-induced apoptosis Nature 459 2009 428 432
6. K.E. Gascoigne, and S.S. Taylor Cancer cells display profound intra- and interline variation following prolonged exposure to antimitotic drugs Cancer Cell 14 2008 111 122
7. S.V. Sharma, D.Y. Lee, B. Li, M.P. Quinlan, F. Takahashi, S. Maheswaran, U. McDermott, N. Azizian, L. Zou, and M.A. Fischbach A chromatin-mediated reversible drug-tolerant state in cancer cell subpopulations Cell 141 2010 69 80
8. S. Huang Non-genetic heterogeneity of cells in development: More than just noise Development 136 2009 3853 3862
9. M. Niepel, S.L. Spencer, and P.K. Sorger Non-genetic cell-to-cell variability and the consequences for pharmacology Curr. Opin. Chem. Biol. 13 2009 556 561
10. T. Kalmar, C. Lim, P. Hayward, S. Muñoz-Descalzo, J. Nichols, J. Garcia-Ojalvo, and A. Martinez Arias Regulated fluctuations in nanog expression mediate cell fate decisions in embryonic stem cells PLoS Biol. 7 2009 e1000149
11. L.C. Cantley The phosphoinositide 3-kinase pathway Science 296 2002 1655 1657 (Pubitemid 34579158)
12. J.A. Engelman Targeting PI3K signalling in cancer: Opportunities, challenges and limitations Nat. Rev. Cancer 9 2009 550 562
13. K.D. Courtney, R.B. Corcoran, and J.A. Engelman The PI3K pathway as drug target in human cancer J. Clin. Oncol. 28 2010 1075 1083
14. T.L. Yuan, and L.C. Cantley PI3K pathway alterations in cancer: Variations on a theme Oncogene 27 2008 5497 5510
15. S.J. Isakoff, J.A. Engelman, H.Y. Irie, J. Luo, S.M. Brachmann, R.V. Pearline, L.C. Cantley, and J.S. Brugge Breast cancer-associated PIK3CA mutations are oncogenic in mammary epithelial cells Cancer Res. 65 2005 10992 11000 (Pubitemid 41713369)
16. S. Kang, A.G. Bader, and P.K. Vogt Phosphatidylinositol 3-kinase mutations identified in human cancer are oncogenic Proc. Natl. Acad. Sci. USA 102 2005 802 807 (Pubitemid 40282746)
17. Y. Samuels, L.A. Diaz Jr. , O. Schmidt-Kittler, J.M. Cummins, L. Delong, I. Cheong, C. Rago, D.L. Huso, C. Lengauer, and K.W. Kinzler Mutant PIK3CA promotes cell growth and invasion of human cancer cells Cancer Cell 7 2005 561 573 (Pubitemid 40799249)
18. J. Debnath, K.R. Mills, N.L. Collins, M.J. Reginato, S.K. Muthuswamy, and J.S. Brugge The role of apoptosis in creating and maintaining luminal space within normal and oncogene-expressing mammary acini Cell 111 2002 29 40
19. J. Debnath, S.J. Walker, and J.S. Brugge Akt activation disrupts mammary acinar architecture and enhances proliferation in an mTOR-dependent manner J. Cell Biol. 163 2003 315 326 (Pubitemid 37363132)
20. S.M. Brachmann, K. Ueki, J.A. Engelman, R.C. Kahn, and L.C. Cantley Phosphoinositide 3-kinase catalytic subunit deletion and regulatory subunit deletion have opposite effects on insulin sensitivity in mice Mol. Cell. Biol. 25 2005 1596 1607 (Pubitemid 40282598)
21. K. Ueki, D.A. Fruman, S.M. Brachmann, Y.H. Tseng, L.C. Cantley, and C.R. Kahn Molecular balance between the regulatory and catalytic subunits of phosphoinositide 3-kinase regulates cell signaling and survival Mol. Cell. Biol. 22 2002 965 977 (Pubitemid 34053073)
22. J. Luo, S.J. Field, J.Y. Lee, J.A. Engelman, and L.C. Cantley The p85 regulatory subunit of phosphoinositide 3-kinase down-regulates IRS-1 signaling via the formation of a sequestration complex J. Cell Biol. 170 2005 455 464 (Pubitemid 41126944)
23. C.M. Taniguchi, J.O. Aleman, K. Ueki, J. Luo, T. Asano, H. Kaneto, G. Stephanopoulos, L.C. Cantley, and C.R. Kahn The p85alpha regulatory subunit of phosphoinositide 3-kinase potentiates c-Jun N-terminal kinase-mediated insulin resistance Mol. Cell. Biol. 27 2007 2830 2840 (Pubitemid 46581299)
24. K. Ueki, D.A. Fruman, C.M. Yballe, M. Fasshauer, J. Klein, T. Asano, L.C. Cantley, and C.R. Kahn Positive and negative roles of p85 alpha and p85 beta regulatory subunits of phosphoinositide 3-kinase in insulin signaling J. Biol. Chem. 278 2003 48453 48466 (Pubitemid 37523301)
25. S.R. Lakhani, J. Jacquemier, J.P. Sloane, B.A. Gusterson, T.J. Anderson, M.J. van de Vijver, L.M. Farid, D. Venter, A. Antoniou, and A. Storfer-Isser Multifactorial analysis of differences between sporadic breast cancers and cancers involving BRCA1 and BRCA2 mutations J. Natl. Cancer Inst. 90 1998 1138 1145 (Pubitemid 28380718)
26. X. Liu, H. Holstege, H. van der Gulden, M. Treur-Mulder, J. Zevenhoven, A. Velds, R.M. Kerkhoven, M.H. van Vliet, L.F. Wessels, and J.L. Peterse Somatic loss of BRCA1 and p53 in mice induces mammary tumors with features of human BRCA1-mutated basal-like breast cancer Proc. Natl. Acad. Sci. USA 104 2007 12111 12116 (Pubitemid 47185638)
27. J.E. Ferrell Jr. , and E.M. Machleder The biochemical basis of an all-or-none cell fate switch in Xenopus oocytes Science 280 1998 895 898 (Pubitemid 28215598)
28. I. Chambers, J. Silva, D. Colby, J. Nichols, B. Nijmeijer, M. Robertson, J. Vrana, K. Jones, L. Grotewold, and A. Smith Nanog safeguards pluripotency and mediates germline development Nature 450 2007 1230 1234
29. H.H. Chang, M. Hemberg, M. Barahona, D.E. Ingber, and S. Huang Transcriptome-wide noise controls lineage choice in mammalian progenitor cells Nature 453 2008 544 547 (Pubitemid 351733323)
30. Z. Chen, L.C. Trotman, D. Shaffer, H.K. Lin, Z.A. Dotan, M. Niki, J.A. Koutcher, H.I. Scher, T. Ludwig, and W. Gerald Crucial role of p53-dependent cellular senescence in suppression of Pten-deficient tumorigenesis Nature 436 2005 725 730 (Pubitemid 41117277)
31. C. Gewinner, Z.C. Wang, A. Richardson, J. Teruya-Feldstein, D. Etemadmoghadam, D. Bowtell, J. Barretina, W.M. Lin, L. Rameh, and L. Salmena Evidence that inositol polyphosphate 4-phosphatase type II is a tumor suppressor that inhibits PI3K signaling Cancer Cell 16 2009 115 125
32. S.M. Maira, F. Stauffer, J. Brueggen, P. Furet, C. Schnell, C. Fritsch, S. Brachmann, P. Chne, A. De Pover, and K. Schoemaker Identification and characterization of NVP-BEZ235, a new orally available dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor with potent in vivo antitumor activity Mol. Cancer Ther. 7 2008 1851 1863
33. P. Cao, S.M. Maira, C. García-Echeverría, and D.W. Hedley Activity of a novel, dual PI3-kinase/mTor inhibitor NVP-BEZ235 against primary human pancreatic cancers grown as orthotopic xenografts Br. J. Cancer 100 2009 1267 1276
34. T.J. Liu, D. Koul, T. LaFortune, N. Tiao, R.J. Shen, S.M. Maira, C. Garcia-Echevrria, and W.K. Yung NVP-BEZ235, a novel dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor, elicits multifaceted antitumor activities in human gliomas Mol. Cancer Ther. 8 2009 2204 2210
35. K.A. Edgar, J.J. Wallin, M. Berry, L.B. Lee, W.W. Prior, D. Sampath, L.S. Friedman, and M. Belvin Isoform-specific phosphoinositide 3-kinase inhibitors exert distinct effects in solid tumors Cancer Res. 70 2010 1164 1172
36. F.I. Raynaud, S.A. Eccles, S. Patel, S. Alix, G. Box, I. Chuckowree, A. Folkes, S. Gowan, A. De Haven Brandon, and F. Di Stefano Biological properties of potent inhibitors of class I phosphatidylinositide 3-kinases: From PI-103 through PI-540, PI-620 to the oral agent GDC-0941 Mol. Cancer Ther. 8 2009 1725 1738
37. A. Alimonti, C. Nardella, Z. Chen, J.G. Clohessy, A. Carracedo, L.C. Trotman, K. Cheng, S. Varmeh, S.C. Kozma, and G. Thomas A novel type of cellular senescence that can be enhanced in mouse models and human tumor xenografts to suppress prostate tumorigenesis J. Clin. Invest. 120 2010 681 693
38. J. Debnath, S.K. Muthuswamy, and J.S. Brugge Morphogenesis and oncogenesis of MCF-10A mammary epithelial acini grown in three-dimensional basement membrane cultures Methods 30 2003 256 268 (Pubitemid 36677560)
39. N. Kotecha, P.O. Krutzik, and J.M. Irish Web-based analysis and publication of flow cytometry experiments Curr. Protoc. Cytom. 2010 Chapter 10, t10, 17